Press Releases September 3, 2026 06:00 AM

Yuanbao Inc. to Announce Second Quarter 2026 Financial Results on Thursday, September 10, 2026

Yuanbao Inc. to Release Q2 2026 Financial Results on September 10 with Earnings Call Scheduled

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
YB

Yuanbao Inc., a technology-driven online insurance distributor in China, announced that it will release its unaudited Q2 2026 financial results on September 10, 2026, prior to the U.S. market open. An earnings call will follow to discuss the results and provide insights into company performance and strategy.

Yuanbao Inc. to Announce Second Quarter 2026 Financial Results on Thursday, September 10, 2026
YB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Yuanbao is a leading online insurance distributor in China leveraging advanced technology to offer customized insurance solutions.
  • The company serves over ten million insurance consumers with a comprehensive service cycle from recommendation to post-sales support.
  • Yuanbao collaborates deeply with insurance carriers to tailor products and improve consumer engagement, driving scalable distribution.

BEIJING, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Yuanbao Inc. (“Yuanbao” or the “Company”) (NASDAQ: YB), a leading technology-driven online insurance distributor in China, today announced that it will release its second quarter 2026 unaudited financial results on Thursday, September 10, 2026, before the open of the U.S. markets.

The Company’s management will hold an earnings conference call at 8:00 A.M. U.S. Eastern Time on September 10, 2026 or 8:00 P.M. Beijing Time to discuss the financial results.

Participants should complete online registration using the link provided below at least 15 minutes before the scheduled start time. Upon registration, participants will receive the conference call access information, including dial-in numbers, a personal PIN and an e-mail with detailed instructions to join the conference call.

Participant Online Registration:
https://register-conf.media-server.com/register/BI30a562cd1000443a9c1521bedb39a2df

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at ir.yb-inc.com.

About Yuanbao Inc.

Yuanbao Inc. is a leading technology-driven online insurance distributor in China, committed to protecting health and well-being through innovative technology. Leveraging its proprietary consumer service cycle engine and advanced technologies, Yuanbao delivers customized insurance solutions from its partnered insurance carriers to over ten million insurance consumers throughout the entire insurance lifecycle, ranging from personalized recommendations to post-sales services. Through deep collaboration with insurance carriers and the use of data-driven insights, Yuanbao empowers carriers to tailor flagship products, enhances consumer engagement, and drives scalable and efficient distribution.

For more information, please visit ir.yb-inc.com.

For investor and media inquiries, please contact:

In China:

Yuanbao Inc.
E-mail: ir@yb-inc.com

Piacente Financial Communications
Helen Wu
Tel: +86-10-6508-0677
E-mail: yb@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yb@thepiacentegroup.com


Risks

  • The company's Q2 2026 financial performance is currently unknown and may impact future stock performance.
  • Operating primarily in the Chinese insurance market exposes Yuanbao to regulatory and market risks within the insurance and technology sectors.
  • The competitive landscape for online insurance distribution in China could impact Yuanbao's growth and profitability.

More from Press Releases

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 Sep 3, 2026 Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference Sep 3, 2026 Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 Sep 3, 2026 C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting Sep 3, 2026 LeonaBio to Participate in Cantor Global Healthcare Conference 2026 Sep 3, 2026